One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium

TARRYTOWN, N.Y. , Feb. 9, 2019 /PRNewswire/ —  Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious vision-threatening complications EYLEA diabetic retinopathy sBLA target action date of May 13, 2019 Regeneron Pharmaceuticals, Inc.

Original Source